Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02293980
Other study ID # 3795-001
Secondary ID PT2385-101MK-379
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date November 25, 2014
Est. completion date November 30, 2026

Study information

Verified date May 2024
Source Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PART 1: The primary objective of this study is to identify the maximum tolerated dose (MTD) of MK-3795, formerly called PT2385 and/or the recommended Phase 2 dose (RP2D) of MK-3795 in patients with advanced clear cell renal cell carcinoma (ccRCC). PART 2: The primary objective of this study is to identify the MTD of MK-3795 up to the RP2D, in combination with nivolumab, in patients with advanced ccRCC.As of Amendment 09 (29 Mar 2024), participants with advanced ccRCC will transition from MK-3795 to belzutifan (MK-6482) in combination with nivolumab or belzutifan alone. PART 3: The primary objective of this study is to identify the MTD of MK-3795 up to the RP2D, in combination with cabozantinib tablets, in patients with advanced ccRCC.


Description:

PART 1: This is a Phase 1, multiple-dose, dose-escalation trial of MK-3795, where patients with advanced ccRCC will be assigned to sequential dose cohorts. Patient safety will be monitored with frequent physical examinations, vital sign measurements, electrocardiograms (ECGs), and hematology and chemistry laboratory studies, and by recording all adverse events (AEs). Blood will be obtained for analysis of the concentration of MK-3795 and to assess biomarkers. PART 2: This is a Phase 1 trial of MK-3795 in combination with nivolumab, where patients with advanced ccRCC will be assigned to dose cohorts. Patient safety will be monitored with frequent physical examinations, vital sign measurements, ECGs, and hematology and chemistry laboratory studies, and by recording all AEs. Blood will be obtained for analysis of the concentration of MK-3795 and to assess biomarkers. As of Amendment 09 (29 Mar 2024), participants with advanced ccRCC will transition from MK-3795 to belzutifan in combination with nivolumab or belzutifan alone. PART 3: This is a Phase 1 trial of MK-3795 in combination with cabozantinib tablets, where patients with advanced ccRCC will be assigned to dose cohorts. Patient safety will be monitored with frequent physical examinations, vital sign measurements, ECGs, and hematology and chemistry laboratory studies, and by recording all AEs. Blood will be obtained for analysis of the concentration of MK-3795 and cabozantinb and to assess biomarkers.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 110
Est. completion date November 30, 2026
Est. primary completion date January 31, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria PART 1 - Has locally advanced or metastatic clear cell renal cell carcinoma (ccRCC) and has progressed during treatment with at least one prior therapeutic regimen - Has a life expectancy of = 3 months - Has adequate organ function - Able to swallow oral medications PART 2 - In addition to PART 1 - Received no more than three prior systemic treatment regimens in the advanced or metastatic setting - Must have received at least one but not more than two prior anti-angiogenic therapy regimens PART 3 - In addition to PART 1 - Must have received at least one vascular endothelial growth factor receptor (VEGFR) targeting tyrosine kinase inhibitor Exclusion Criteria PART 1 - Has a history of untreated brain metastasis or history of leptomeningeal disease or spinal cord compression - Has failed to recover from the reversible effects of prior anticancer therapy - Has uncontrolled or poorly controlled hypertension - Is receiving warfarin anticoagulant therapy or expected to require warfarin - Has had any major cardiovascular event within 6 months prior to study drug administration - Has any other clinically significant cardiac, respiratory, or other medical or psychiatric condition that might interfere with participation in the trial or interfere with the interpretation of trial results - Has had major surgery within 4 weeks before first study drug administration - Has known human immunodeficiency virus (HIV) infection - Has an active infection requiring systemic treatment - Is participating in another therapeutic clinical trial PART 2 - In addition to PART 1 - Has received prior immunotherapy - Has any active or recent history of a known or suspected autoimmune disease PART 3 - In addition to PART 1 - Has gastrointestinal (GI) disorders - Has any history of congenital long QT syndrome

Study Design


Intervention

Drug:
MK-3795
Oral administration
Nivolumab
IV infusion
Cabozantinib
Oral administration
Bezlutifan
Oral administration

Locations

Country Name City State
United States Emory University Winship Cancer Institue Atlanta Georgia
United States University of Colorado Cancer Center Aurora Colorado
United States University of Maryland - Greenebaum Cancer Center Baltimore Maryland
United States Beth Israel Deconess Medical Center Boston Massachusetts
United States Dana-Farber Cancer Institute Boston Massachusetts
United States Massachusetts General Hospital - Cancer Center Boston Massachusetts
United States Rush University Medical Center Chicago Illinois
United States Cleveland Clinic Cleveland Ohio
United States The Ohio State University Columbus Ohio
United States UT Southwestern Medical Center Dallas Texas
United States Barbara Ann Karmanos Cancer Institute Detroit Michigan
United States Virginia Cancer Specialists Fairfax Virginia
United States The West Clinic Germantown Tennessee
United States Indiana University Simon Cancer Center Indianapolis Indiana
United States Cedars-Sinai Medical Center Los Angeles California
United States University of Miami - Sylvester Comprehensive Cancer Center Miami Florida
United States Medical College of Wisconsin Milwaukee Wisconsin
United States Tennessee Oncology Nashville Tennessee
United States Vanderbilt Medical Center Nashville Tennessee
United States Yale School of Medicine New Haven Connecticut
United States Mount Sinai Heath System New York New York
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States University of Pittsburg Medical Center Pittsburgh Pennsylvania
United States Swedish Cancer Institute Seattle Washington
United States University of Washington Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Tolerated Dose (MTD) MTD of MK-3795 will be determined. MTD will be defined as the dose level at which 2 or more participants experience a dose limiting toxicity (DLT) which will be deemed intolerable and the dose level below will be declared the MTD. Part 1: 3 Weeks, Part 2: 4 Weeks, Part 3: 4 Weeks
Primary Recommended Phase 2 Dose (RP2D) The RP2D of MK-3795 will be determined. The RP2D will be determined based on the MTD (or the optimal biological dose (OBD) if the MTD is not identified), the overall safety profile with continued treatment, and pharmacokinetic (PK) profile. Part 1: 3 Weeks; Part 2: 4 Weeks, Part 3: 4 Weeks
Secondary Number of Participants Who Experience an Adverse Event (AE) An AE is defined as any untoward medical occurrence in a participant administered a study treatment which did not necessarily have to have a causal relationship with this treatment. An AE could be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of study treatment, is also an AE. The number of participants who experience an AE will be presented. Up to approximately 9 years
Secondary Best Response (BOR) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) BOR is the best tumor response recorded up until documentation of progression of disease (PD) or death from any cause, or until the patient withdraws consent. Per RECIST 1.1, PD is defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of =5 mm. The appearance of one or more new lesions is also considered PD. Up to approximately 1 year
Secondary Objective Response Rate (ORR) per RECIST 1.1 ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR based on RECIST 1.1 will be presented. Up to approximately 1 year
Secondary Progression-Free Survival (PFS) per RECIST 1.1 PFS is defined as the time from the first dose of MK-3795 to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of =5 mm. The appearance of one or more new lesions is also considered PD. Up to approximately 9 years
Secondary Duration of Response (DOR) per RECIST 1.1 For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The median DOR will be presented. Up to approximately 1 year
Secondary Clinical Benefit Rate (CBR) per RECIST 1.1 CBR is defined as the percentage of participants who achieve clinical benefit. Clinical benefit is defined as a best response of CR (Disappearance of all target lesions), PR (At least a 30% decrease in the sum of diameters of target lesions) or stable disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease [PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD.]). Up to approximately 1 year
Secondary Maximum concentration (Cmax) of Study Treatment Blood samples will be collected at designated timepoints for the determination of Cmax. Cmax was defined as the maximum concentration of study treatment is reached. At designated timepoints (up to 106 days)
Secondary Time to Maximum Concentration (Tmax) of Study Treatment Blood samples will be collected at designated timepoints the determination of Tmax. Tmax is defined as the time to the maximum concentration of study treatment reached. At designated timepoints (up to 106 days)
Secondary Terminal half-life (t½?z) of Study Treatment Blood samples will be collected at designated timepoints for the determination of (t½?z). (t½?z) is defined as the time required for the plasma concentration of study drug to decrease 50% in the final stage of its elimination. At designated timepoints (up to 106 days)
Secondary Area Under the Concentration-Time Curve From 0 to Infinity (AUC0-inf) of Study Treatment Blood samples will be collected at designated timepoints for the determination of AUC0-inf. AUC0-inf is the area under the serum concentration-time curve from time zero to infinity. At designated timepoints (up to 106 days)
Secondary Area Under the Concentration-Time Curve From 0 to Inf Extrapolated (AUC0-inf Extrap) of Study Treatment Blood samples were collected at designated timepoints for the determination of AUC0-inf extrapolated. AUC0-inf extrapolated is a measure of mean concentration in serum from time zero to infinity. At designated timepoints (up to 106 days)
Secondary Area Under the Concentration-Time Curve From 0 to 12 Hours (AUC0-12) of Study Treatment Blood samples were collected at designated timepoints for the determination of AUC0-12. AUC0-12 is a measure of mean concentration in serum from time zero to 12 hours. At designated timepoints (up to 106 days)
Secondary Area Under the Plasma Concentration-time Curve From Time 0 to Last (AUC0-last) of Study Treatment Blood samples were collected at designated timepoints for the determination of AUC0-last. AUC0-last is a measure of mean concentration in serum from time zero to last measurable concentration. At designated timepoints (up to 106 days)
Secondary Apparent Volume of Distribution (Vz/F) of Study Treatment Blood samples were collected at designated timepoints for the determination of Vz/F. Vz/F is a the volume of study drug that would need to be uniformly distributed to produce desired serum concentration. F is the fraction of the dose absorbed. At designated timepoints (up to 106 days)
Secondary Apparent Clearance (CL/F) of Study Treatment Blood samples were collected at designated timepoints for the determination of CL/F. CL/F is a the volume of plasma from which study drug was eliminated per unit time. F is the fraction of the dose absorbed. At designated timepoints (up to 106 days)
Secondary Accumulation Ratio (RAC) Blood samples were collected at designated timepoints for the determination of RAC. RAC is calculated as AUC0-12 at steady state divided by AUC0-12 after first dose. At designated timepoints (up to 106 days)
Secondary Mean Plasma Concentration of Erythropoietin (EPO) Level Blood samples will be collected at designated timepoints to measure EPO level. The mean concentration of EPO level will be reported. At designated timepoints (up to 106 days)
Secondary Mean Plasma Concentration of Plasminogen Activator Inhibitor 1 (PAI-1) Level Blood samples will be collected at designated timepoints to measure PAI-1 level. The mean concentration of PAI-1 level will be reported. At designated timepoints (up to 106 days)
Secondary Mean Plasma Concentration of Insulin Growth Factor Binding Protein 3 (IGFBP3) Level Blood samples will be collected at designated timepoints to measure IGFBP3 level. The mean concentration of IGFBP3 level will be reported. At designated timepoints (up to 106 days)
Secondary Mean Plasma Concentration of Vascular Endothelial Growth Factor A (VEGFa) Level Blood samples will be collected at designated timepoints to measure VEGFa level. The mean concentration of VEGFa level will be reported. At designated timepoints (up to 106 days)
Secondary Percent Change from Baseline in the EPO Level Blood samples will be collected at designated timepoints to measure EPO level. The percent change from baseline in EPO level up to approximately Week 16 will be reported. Baseline and up to approximately Week 16
Secondary Percent Change from Baseline in the PAI-1 Level Blood samples will be collected at designated timepoints to measure PAI-1 level. The percent change from baseline in PAI-1 level up to approximately Week 16 will be reported. Baseline and up to approximately Week 16
Secondary Percent Change from Baseline in the IGFBP3 Level Blood samples will be collected at designated timepoints to measure IGFBP3 level. The percent change from baseline in IGFBP3 level up to approximately Week 16 will be reported. Baseline and up to approximately Week 16
Secondary Percent Change from Baseline in the VEGFa Blood samples will be collected at designated timepoints to measure VEGFa level. The percent change from baseline in VEGFa level up to approximately Week 16 will be reported. Baseline and up to approximately Week 16
Secondary Antitumor Activity Antitumor activity will be assessed by non-contrast or contrast computerized tomography (CT) or magnetic resonance imaging (MRI) at baseline, during Week 6, and every 9 weeks thereafter up to approximately 1 year. Baseline, at Week 6 and every 9 Weeks thereafter up to approximately 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04987203 - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Phase 3
Recruiting NCT06391879 - Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Completed NCT02853344 - Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) Phase 2
Terminated NCT04088500 - A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma Phase 2
Completed NCT05070637 - Circulating Tumor Cell Reducing No-touch Nephrectomy N/A
Active, not recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Not yet recruiting NCT06049030 - A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT01358721 - Phase I Biomarker Study (BMS-936558) Phase 1
Active, not recruiting NCT04503148 - Anesthesia and Cancer Study: Renal Cell Carcinoma N/A
Completed NCT02386826 - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Phase 1
Not yet recruiting NCT05808608 - A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma Phase 1/Phase 2
Withdrawn NCT03323710 - Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma Phase 2
Completed NCT03052504 - Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy